Table 3. Sensitivity of bacterial strains to the action of different antibiotics (results expressed in μg.mL-1) assessed by Vitek® 2.
| Antibiotics | MIC (Interpretation) | |
|---|---|---|
| KP-KPC | SM-KPC | |
| Amikacin | > 32 (R) | 16 (S) |
| Ampicillin | > 16 (R) | > 16 (R) |
| Aztreonam | > 16 (R) | > 16 (R) |
| Cefoxitin | > 16 (R) | > 16 (R) |
| Ceftazidime | 16 (R) | 8 (R) |
| Cefepime | > 16 (R) | 8 (R) |
| Ciprofloxacin | > 2(R) | > 2 (R) |
| Ertapenem | > 4 (R) | > 4 (R) |
| Gentamicin | > 8 (R) | ≤ 2 (S) |
| Imipenem | > 8 (R) | > 8 (R) |
| Levofloxacin | > 4 (R) | > 4 (R) |
| Meropenem | > 8 (R) | > 8 (R) |
| Nitrofurantoin | > 64 (R) | > 64 (R) |
| Piperacillin/Tazobactam | > 64/4 (R) | 64/4 (R) |
| Polymyxin B | ≤ 1 (S) | (IR) |
| Tigecycline | 2 (I) | 4 (R) |
| Sulfamethoxazole/Trimethoprim | > 4/76 (R) | ≤ 1/19 (S) |
KP-KPC: carbapenemase-producing K. pneumoniae; MIC: minimal inhibitory concentration; SM-KPC: carbapenemase-producing S. marcescens; (S): susceptibility; (I): intermediate; (R): resistance; (IR): intrinsic resistance.